Sunitinib in urothelial cancer: Clinical, pharmacokinetic, and immunohistochemical study of predictors of response
Carcinoma, Transitional Cell
Vascular Endothelial Growth Factor Receptor-2
Clinical and molecular biomarkers of response to sunitinib may have clinical relevance and require prospective validation. There is an urgent need for predictive biomarkers to guide the management of UC.